Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled Study

Nickel, J. Curtis; O’Leary, Michael P.; Lepor, Herbert; Caramelli, Kim E.; Thomas, Heather; Hill, Lawrence A.; Hoel, Gary

doi:10.1016/j.juro.2011.03.028

Cited by 54 publications

(49 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all, 10 placebo-controlled RCTs (n = 58-272) were identified that evaluated a-adrenergic antagonists (tamsulosin [53][54][55], alfuzosin [56,57], doxazosin [58,59], terazosin [60,61] and silodosin [62]) in CBP and CP/CPPS. Most (eight) showed positive results, with significant differences vs placebo in NIH-CPSI total, urinary symptom, pain, and/or QoL scores [54][55][56][57]59,60], or in scores using other validated symptom scoring tools [58,61].…”

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Rees

Abrahams

Doble³

et al. 2015

BJU International

246

193

View full text Add to dashboard Cite

ObjectivesTo improve awareness and recognition of chronic bacterial prostatitis (CBP) and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) among non-specialists and patients. To provide guidance to healthcare professionals treating patients with CBP and CP/CPPS, in both non-specialist and specialist settings. To promote efficient referral of care between nonspecialists and specialists and the involvement of the multidisciplinary team (MDT). Patients and MethodsThe guideline population were men with CBP or CP/CPPS (persistent or recurrent symptoms and no other urogenital pathology for ≥3 of the previous 6 months). Consensus recommendations for the guidelines were based on a search to identify literature on the diagnosis and management of CBP and CP/CPPS (published between 1999 and February 2014). A Delphi panel process was used where high-quality, published evidence was lacking. ResultsCBP and CP/CPPS can present with a wide range of clinical manifestations. The four main symptom domains are urogenital pain, lower urinary tract symptoms (LUTSvoiding or storage symptoms), psychological issues and sexual dysfunction. Patients should be managed according to their individual symptom pattern. Options for first-line treatment include antibiotics, a-adrenergic antagonists (if voiding LUTS are present) and simple analgesics. Repeated use of antibiotics, such as quinolones, should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause. Early use of treatments targeting neuropathic pain and/or referral to specialist services should be considered for patients who do not respond to initial measures. An MDT approach (urologists, pain specialists, nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioural therapists/psychologists, and sexual health specialists) is recommended. Patients should be fully informed about the possible underlying causes and treatment options, including an explanation of the chronic pain cycle. ConclusionChronic prostatitis can present with a wide variety of signs and symptoms. Identification of individual symptom patterns and a symptom-based treatment approach are recommended. Further research is required to evaluate management options for CBP and CP/CPPS.

show abstract

Section: A-adrenergic Antagonistsmentioning

confidence: 99%

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Rees

Abrahams

Doble³

et al. 2015

BJU International

246

193

View full text Add to dashboard Cite

show abstract

“…Silodosin at 4 mg was shown to be more effective than placebo in improving CPSI (statistical significance achieved within the urinary symptom and quality-of-life impact domains). GRA was also significantly greater for the treatment group (56% for 4 mg of silodosin vs 34% for placebo) [30]. The differences in treatment effects observed in this and other α-blocker studies, as explained by the authors, may be due to differences in study design, α-blockers, and study population.…”

Section: Management Of Lower Urinary Tract Symptoms Associated With Umentioning

confidence: 41%

Lower Urinary Tract Symptoms Associated with Male Urologic Pelvic Pain Syndrome

Potts

2011

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

A common urologic diagnosis in men, urologic chronic pelvic pain (UCPP) is often associated with bothersome lower urinary tract symptoms (LUTS), which contribute to the diminished quality of life observed in these patients. The differential diagnosis of LUTS as a separate entity should be considered during evaluation of UCPP patients to exclude other urologic or neurological conditions. However, most patients can be afforded improvement of LUTS as they receive appropriate therapy for UCPP.

show abstract

“…Nickel et al reported in their research that Silodosin was effective for improvement of symptom and quality of life of in patients with CP/CPPS [14]. And it was further reported that terazosin [15] and alfuzosin [16] that are alpha blockers are also effective.…”

Section: Monotherapymentioning

confidence: 96%

“…The CPSI score had shown dramatic change [36]. Other options such as tadalafil which is a PDE5 inhibitor, which can treat erectile dysfunction, lower urinary tract symptoms and possibly the symptoms of CP/CPPS as well [37].…”

Section: 3-1 U: Urinarymentioning

confidence: 99%

Recent trend of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) management

Lee

2017

Hanyang Med Rev

View full text Add to dashboard Cite

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition. However, many of the traditional therapies like monotherapy used in clinical practice fail to show efficacy. There is no one particular treatment to be recommended as monotherapy for CP/CPPS. The new concept of treatment which is 'UPOINT' is introduced. The major barrier in treating men with CP/CPPS is the heterogenous nature of this syndrome. In order to treat appropriately, the patient should be evaluated individually to assess the nature of symptoms. To evaluate patients with chronic urologic pelvic pain, a six-point clinical phenotyping system has been developed. The clinical domains are urinary symptoms, psychosocial dysfunction, organ specific findings, infection, neurologic/systemic, and tenderness of muscles, which produces the acronym 'UPOINT' . This clinical phenotyping system may provide a useful and clinically relevant framework for multimodal therapy for the treatment of CP/CPPS. However, the concept of UPOINT needs randomization, placebo or sham control studies to show verified treatment.

show abstract

Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled Study

Abstract: Silodosin 4 mg relieved symptoms and improved quality of life in men with chronic prostatitis/chronic pelvic pain syndrome but its efficacy requires confirmation in additional studies.

Cited by 54 publications

References 21 publications

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline

Lower Urinary Tract Symptoms Associated with Male Urologic Pelvic Pain Syndrome

Recent trend of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) management

Contact Info

Product

Resources

About